1.00Open1.00Pre Close0 Volume141 Open Interest17.00Strike Price0.00Turnover116.25%IV3.09%PremiumMay 16, 2025Expiry Date0.46Intrinsic Value100Multiplier8DDays to Expiry0.54Extrinsic Value100Contract SizeAmericanOptions Type0.5975Delta0.1297Gamma12.25Leverage Ratio-0.0767Theta0.0019Rho7.32Eff Leverage0.0099Vega
MediWound Stock Discussion
MediWound Delivers Record Revenue Growth: NexoBrid Sales Soar 42% Amid Major Funding Wins
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet